Dossier assessment

Filgotinib (rheumatoid arthritis) - Benefit assessment according to §35a Social Code Book V

Status
Status: Commission completed
Project no.
A20-90
Last updated

Report documents

  1. Extract of dossier assessment

    Filgotinib (rheumatoid arthritis) - Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 707 kB, EN, not accessible
  2. Dossier assessment

    Filgotinib (rheumatoid arthritis) - Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 687 kB, DE, not accessible

Dossier assessment

Indication:

Adults with moderate to severe active rheumatoid arthritis who have responded inadequately to, or who are intolerant to one or more DMARDs

Result of dossier assessment:

First-time therapy with bDMARDs or tsDMARDs indicated: in combination with MTX, hint of minor added benefit. Other constellations: added benefit not proven.

Project details

Project no.
A20-90
Commission
Commission awarded on 15.10.2020 by the Federal Joint Committee (GBA).
Report type
Dossier assessment
Status
Commission completed
Department/Division
Drug Assessment
Topic
Muscles, bones and joints
Note

After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.

Connected Projects

  1. Dossier assessment

    Filgotinib (ulcerative colitis) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A21-155
    Last updated

    Status: Commission completed

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form